Evolocumab Treatment Failure Following Covid-19 Mrna Vaccination

Park, Byung Joon; Makaryus, John N.; Hirsh, Benjamin; Boutis, Loukas

doi:10.1016/s0735-1097(22)03381-2

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Так, по сравнению с монотерапией алирокумабом его применение в комбинации со статинами приводило к снижению системного воздействия на 40%, в комбинации с фибратами -на 35% 4 . Определенный повод для беспокойства представляет опубликованный в 2022г случай снижения эффективности эволокумаба после введения второй дозы мРНК вакцины от новой коронавирусной инфекции (COVID-19) [87].…”

Section: Discussionunclassified

New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy

Zyryanov

Бутранова

2022

Russ J Cardiol

View full text Add to dashboard Cite

The spread of cardiovascular diseases has the nature of an epidemic, which is enhanced by lipid profile disorders, manifested by hypercholesterolemia. Numerous conventional pharmacological tools for lowering cholesterol associated with low density lipoproteins do not make it possible to achieve target values in various categories of patients. Inhibition of proprotein convertase subtilisin/ kexin type 9 (PCSK9) is a promising target in the management of patients with atherosclerotic diseases and includes two main tools — monoclonal antibodies (Alirocumab and Evolocumab) and a small interfering RNA drug (Inclisiran). The presented review is devoted to a comparative analysis of the efficacy and safety of drugs from these groups.

show abstract

Section: Discussionunclassified